A new study demonstrates the effectiveness of Pfizer's Aromasin for early breast cancer treatment, with improved relapse-free survival and disease-free survival rates. The B-33 trial found that Aromasin was well-tolerated and showed a significant improvement in patients who received it after five years of tamoxifen.
The study found ZYVOX had better cure rates (94.4% vs 90.4%) and shorter IV treatment duration (2 days vs 9.1 days) for patients treated with ZYVOX compared to vancomycin. Additionally, ZYVOX reduced hospital length of stay by a mean of 2.4 days.
A study found that Viagra took effect within 14-20 minutes for many men, with over half experiencing erections leading to successful intercourse. The medication was well-tolerated, with no patients discontinuing treatment due to side effects.